D007252Chemicals & DrugsD20.215.894.899.302362690.786772Influenza VaccinesFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation Resourcevivo:orcidIdORCID idPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonDivision of ResearchKaiser Permanente Northern CaliforniaNicolaKleinNicola P. Klein, MD, PhD37.80931810000000-122.26769880000000113Klein, Nicola0000-0003-1777-4814Director, Kaiser Permanente Vaccine Study CenterBruceFiremanBruce H. Fireman, MA37.80931810000000-122.26769880000000151Fireman, Bruce0000-0003-1652-985XResearch Scientist IIIKaiser Permanente ColoradoKaiser Permanente Northwest1Senior Investigator / Research Scientist IIIAllisonNalewayAllison L. Naleway, PhD45.54734220000000-122.6817828000000011Naleway, Allison0000-0001-5747-4643Center for Health Research Distinguished InvestigatorJasonGlanzJason M. Glanz, PhD39.67327100000000-104.8699090000000036Glanz, Jason0000-0002-1950-7034Senior InvestigatorMatthewDaleyMatthew F. Daley, MD39.67327100000000-104.8699090000000044Daley, Matthew0000-0003-1309-4096Senior Clinician InvestigatorInstitute for Health ResearchCenter for Health Research37599140Kenigsberg TA, Goddard K, Hanson KE, Lewis N, Klein N, Irving SA, Naleway AL, Crane B, Kauffman TL, Xu S, Daley MF, Hurley LP, Kaiser R, Jackson LA, Jazwa A, Weintraub ESVaccineSimultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines. Vaccine. 2023 09 07; 41(39):5678-5682.Vaccine2023-08-19T00:00:002023Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines.9.639220.019809236research area of0.9924380.0588398218subject area for38091531Hsiao A, Yee A, Fireman B, Hansen J, Lewis N, Klein NPThe New England journal of medicineRecombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age. N Engl J Med. 2023 Dec 14; 389(24):2245-2255.N Engl J Med2023-12-14T00:00:002023Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age.38105137Jackson LA, Stapleton JT, Walter EB, Chen WH, Rouphael NG, Anderson EJ, Neuzil KM, Winokur PL, Smith MJ, Schmader KE, Swamy GK, Thompson AB, Mulligan MJ, Rostad CA, Cross K, Tsong R, Wegel A, Roberts PCVaccineImmunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adults. Vaccine. 2024 Jan 12; 42(2):295-309.Vaccine2023-12-16T00:00:002023Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adults.38177116Liu F, Gross FL, Joshi S, Gaglani M, Naleway AL, Murthy K, Groom HC, Wesley MG, Edwards LJ, Grant L, Kim SS, Sambhara S, Gangappa S, Tumpey T, Thompson MG, Fry AM, Flannery B, Dawood FS, Levine MZNature communicationsRedirecting antibody responses from egg-adapted epitopes following repeat vaccination with recombinant or cell culture-based versus egg-based influenza vaccines. Nat Commun. 2024 Jan 04; 15(1):254.Nat Commun2024-01-04T00:00:002024Redirecting antibody responses from egg-adapted epitopes following repeat vaccination with recombinant or cell culture-based versus egg-based influenza vaccines.38000964Payne AB, Ciesla AA, Rowley EAK, Weber ZA, Reese SE, Ong TC, Vazquez-Benitez G, Naleway AL, Klein NP, Embi PJ, Grannis SJ, Kharbanda AB, Gaglani M, Tenforde MW, Link-Gelles R, VISION NetworkVaccineImpact of accounting for correlation between COVID-19 and influenza vaccination in a COVID-19 vaccine effectiveness evaluation using a test-negative design. Vaccine. 2023 Dec 12; 41(51):7581-7586.Vaccine2023-11-23T00:00:002023Impact of accounting for correlation between COVID-19 and influenza vaccination in a COVID-19 vaccine effectiveness evaluation using a test-negative design.true1Center for Health Research Distinguished InvestigatorCenter for Health Research Distinguished Investigatortrue1Director, Kaiser Permanente Vaccine Study CenterDirector, Kaiser Permanente Vaccine Study Centertrue1Research Scientist IIIResearch Scientist IIItrue1Senior InvestigatorSenior Investigatortrue1Senior Clinician InvestigatorSenior Clinician Investigator